Multi-dimensional Multi-omics Integrative Study to Identify Target Genes for Ischemic Stroke and Related Chronic Pain

Yuanlin Wang1,2, Dan Liu3, Shuai Wang4

  • 1Department of Anesthesiology, Tianjin Medical University General Hospital, Tianjin, China. wyl1996@tmu.edu.cn.

Insights

This study identifies S100a6 as a key gene linking ischemic stroke and chronic pain. Activating S100a6 shows protective effects against stroke and reduces pain, suggesting it as a potential drug target.

Area of Science:

  • Neuroscience
  • Immunology
  • Genetics

Background:

  • Chronic pain is a common complication following ischemic stroke.
  • Understanding immune-related cell death in ischemic stroke is crucial for managing its after-effects.

Purpose of the Study:

  • To identify immune-related cell death target genes in ischemic stroke.
  • To explore the role of these genes in chronic pain development.
  • To evaluate S100a6 as a potential therapeutic target.

Main Methods:

  • Analysis of mRNA and microRNA transcriptomics data from a mouse MCAO model.
  • Single-cell and spatial transcriptomic analysis of brain tissue.
  • Genome-Wide Association Studies (GWAS), eQTLs, and Mendelian randomization (MR) for causal inference and drug target evaluation.
  • Polymerase Chain Reaction (PCR) validation in an animal model.

Main Results:

  • Five core mRNAs (S100a6, Anxa3, Ncf4, Capg, Arpc1b) and one microRNA (miR-298-5p) were identified as biomarkers for immune-related cell death.
  • S100a6 was highlighted for its significant role, involved in CD4+ γδ T cell differentiation and immune activation post-ischemic stroke.
  • Activation of S100a6 demonstrated a potential to decrease the probability of developing ischemic stroke by 23-54% and protect neuronal function.

Conclusions:

  • S100a6 plays a causal protective role in ischemic stroke and associated chronic pain.
  • S100a6 is identified as a promising therapeutic target for ischemic stroke and chronic pain.
  • The study elucidates the intricate relationship between cell death, immune response, and neurological complications after stroke.

Related Concept Videos

Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
12.6K
Analgesia and Pain Management01:25

Analgesia and Pain Management

Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
3.3K
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
159
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
121